These inconsistencies in different experimental settings raised the question as to whether sNKG2D-L is immune stimulatory or inhibitory in the context of tumor and raised the concern as to whether soluble human NKG2D ligand is a cancer therapeutic target. Here, KLRK1 is linked to neoplasm.